Neurotoxin injection in benign submandibular gland hypertrophy: A first choice treatment by Karapantzou, Chrisanthi et al.
OR I G I N A L R E S E A R CH
Neurotoxin injection in benign submandibular gland
hypertrophy: A first choice treatment
Chrisanthi Karapantzou MD, PhD, MSc1 | Mark Jakob MD, PhD, Prof.2 |
Martin Canis MD, PhD, Prof.2
1Facial Rejuvenation Office, ORL Clinic,
Ludwigs-Maximillians-University Munich,
Munich, Germany
2ORL University Department, Ludwig-
Maximillians University Munich, Munich,
Germany
Correspondence
Chrisanthi Karapantzou, Head of the Facial
Rejuvenation Office, ORL Clinic, Ludwigs-
Maximillians-University Munich,
Marchioninistr. 15, 81377 Munich, Germany.
Email: chrisanthi24@yahoo.gr
Abstract
Background: Various benign clinical entities with a symptomatology of hypertrophic
submandibular glands like sialadenitis, sialadenosis, sialolithiasis, or an ageing neck
have been described. Botulinum toxin type A is an elegant tool in the management of
these conditions.
Methods: This article is an original article, describing the Munich Concept of treating
persistent submandibular swelling with Botulinum Toxin Type A from aesthetic and
functional aspect. To shrink the affected tissue, 15 Units of Botox or Xeomin are
applied in a single injection technique and under ultrasound guidance into the glands.
Therefore, the 100 Units vial is being diluted with 3.5 of NaCl.
Results: Intraglandular injections, using a specific dilution and dosage of the neuro-
toxin preparations, are very effective in the management of these swellings, offering
safe and long-lasting results, with a high satisfaction rate. Our working group treated
in the last 18 months 23 patients with benign, bilateral submandibular gland hyper-
trophies, which did not have any major complications.
Conclusion: As there is not yet described an ideal therapeutic strategy for the man-
agement of this symptomatology, we suggest, based on our experience, a concept
with very promising results from functional and cosmetic aspect.
Several interdisciplinary indications of the head and neck area have been
managed effectively with the utilization of botulinum toxin type A, since
its first introduction from Scott in 1979.1 Clinical entities that can be
approached with the neurotoxin include facial dystonias, sequelae fol-
lowing facial palsy and other abnormal muscular hyperactivities of the
mimic muscles and the platysma. Identifying and understanding its bio-
chemical mechanism of function expanded its application field in the
treatment of functional and aesthetic disorders. Botulinum toxin leads to
a reversible inhibition of acetylcholine release at the neuromuscular junc-
tion, causing a relaxation of the target musculature.
The observation that botulinum toxin could block the acetylcholine
release also in the autonomous system, as it affects cholinergic
parasympathetic secromotor fibers in sweat and salivary glands, was
essential in the development of new, innovative treatments.2 Frey's
syndrome, hypersalivation, hyperhidrosis, and other secretory dysfunc-
tions could be approached in a minimal invasive way. The effectiveness
of the toxin use in autonomic disorders is being confirmed and empha-
sized through the European Approval of incobotulinumtoxin A, for
treatments of chronic sialorrhea in adult patients. This announcement
in May 2019 made the preparation Xeomin, the first and only to be
approved for this indication in the European Union, following the US
FDA approval in July 2018.3,4
Any botulinum toxin injector might have made the observation
that beneath the salivary flow and parenchymal tension, there can
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also be a visible reduction in the size of the treated glands. Despite
these therapeutic options, there is also another extension in botuli-
num toxin treatments of salivary glands: the aesthetic aspect. Focus-
ing especially on the submandibularis, there are plenty of patients
dealing with benign hypertrophic glands, without having always an
underlying pathology, like a sialadenosis or chronic sialadenitis. In
addition to that, ageing signs near the mandible and neck, where a
bigger size and ptosis of the submandibularis cannot be hidden, play a
determinant role in patients' self-perception. Although post neck- and
facelift patients are left with visibly improved jawlines, the promi-
nence of the uncoverable submandibular gland on an otherwise lifted
and youthful neck causes dissatisfaction and frustration. In these
cases, the intraglandular neurotoxin injections offer an elegant and
safe solution with long-lasting duration of efficacy5 (Figure 1).
Physiologically, the daily salivary production in adults has been
estimated from 0.75 to 1.5 L. The submandibular glands contribute
70% of the total saliva in unstimulated state, the parotid glands 22%,
and the sublingual glands approximately 8%.6 The stimulation of the
submandibular and sublingual glands is from common parasympa-
thetic origin over the submandibular ganglion, whereas one of the
parotid glands is from the ganglion oticum, leading to a specific neuro-
transmitter activation onto the salivary acinar cells. This transmitter is
as in the muscular system, acetylcholine, which binds to muscarinic
receptors causing an intracellular calcium ion activity increase, induc-
ing this way secretion. A sympathetic muscular contraction follows
and enhances saliva expression after its stimulation.7
Main anatomic consideration, prior to toxin application, is its
localization: under the mandibular bone, beneath the platysma, and in
the posterior portion of the submandibular triangle. This triangular
appearing anatomical area is formed by the mandible superiorly, the
anterior belly of the digastric muscle medially, and the posterior digas-
tric belly infero-laterally.8 The gland is located 2 to 3 cm posterior to
the neck midline and has a subdivision in a superficial and a deep lobe,
separated by the mylohyoid muscle. Its excretory duct drains in the
oral cavity at the sublingual caruncle.9 The main role of the gland is
the lubrication of the stomatopharynx, to allow adequate swallowing
act, initiate digestion, protect the duct epithelium from bacteria, and
buffer the pH of the oral cavity.9
From histological aspect, it is a branched tubuloacinar gland, due
to its synthesis of serous and mucinous acini. Numerically, the serous
predominates over the mucous part, but the very active mucous
adenomeres lead to a thicker saliva consistency. Saliva not only has
organic components including enzymes, proteins (mainly amylase),
and immunoglobulines, but also has electrolytes as inorganic compo-
nents.9 Scientifically proven is that the neurotoxin reduces the
amount of the daily saliva, without having an impact on its composi-
tion in organic and inorganic compounds.9
Its blood supply comes from external carotid artery branches, the
facial, and lingual artery, further divided into submental and sublingual
arteries. The facial artery passes from posterior to the gland body. The
venous drainage of the submandibularis is supported by the common
facial and sublingual vein, flowing into the internal jugular vein.10
Various conditions lead to a visible prominence of this gland. Its
malignancies make up 2% of all head and neck tumors. Once affected,
the possibility of an adenoid cystic and mucoepidermoid carcinoma is
with 50% extremely high.11 Botulinum toxin can be used as a therapeutic
tool to control benign hypertrophies of the submandibular tissue, like
sialadenitis, sialadenosis, and sialolithiasis. Sialadenitis is a mostly unilat-
eral inflammation disease, caused by obstructive factors like stones,
trauma, duct stenosis, or infection with bacteria or viruses. Patients may
develop fever, pain, and an enormous glandular edema. Sialadenosis is a
typically bilateral noninflammatory hypertrophy of the submandibular
glands, having its origin in metabolic disorders like anorexia nervosa,
bulimia, and diabetes. Other clinical conditions associated with a high
sialadenosis incidence are alcoholism and non-alcoholic cirrhosis. Gug-
genheimer et al supported that the etiopathological mechanism of
sialadenosis is probably an autonomic disruption of the glandular inner-
vation, based on secretory granules accumulation in acinar cells.12 The
last benign condition accompanied with submandibular swelling is
sialolithiasis. Regardless the etiology of the tissue swelling, every gland
enlargement is associated with pain and superinfection danger, because
of the salivary stasis, as the Wharton duct cannot drain the produced
seromucous saliva into the oral cavity. This situation offers a great milieu
for the development of bacteria.
Every predescribed conditions can be clinically diagnosed, supported
by sonography and if needed CT or MR sialography.9 The initial
F IGURE 1 A 44-year old female
patient with benign bilateral hypertrophy
of the submandibular glands, associated
to a systemic metabolic disorder. Status
of the same patient pre (left picture) and
after intraglandular injection of 15 units
botulinum toxin type A, only 2 weeks
after primary treatment
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therapeutic treatment is conservative including sialagogues, oral hydra-
tion, and antibiotics when inflammation persists or fever occurs. Some-
times salivary stones can be manually palpated when they are localized
within the duct and especially near the caruncel. Often small stones can
be removed under local anesthesia only with duct distension. In some
cases, the stone removal procedure can afford a small papillotomy to pre-
vent future residual conditions. Andwhen conservative treatment fails or
a stone lies within the gland body, leading repeatedly to sialadenitis, sur-
gery is the only recommendation. In all these benign clinical entities, botu-
linum toxin can be used to reduce salivary flow. This quantitative, but not
qualitative limitation in the daily produced saliva secretion, helps in the
prevention of gland tissue inflammation, as the salivary stasis danger
decreases.
1 | METHODS
Technically, botulinum toxin injections into the submandibular glands
may be performed using a blind palpation of the glands or under sono-
graphic or electromyographic guidance, to ensure more precise appli-
cations into the gland body (Figure 2). In our practice, submandibular
glands are treated under ultrasound guided, single injections of
15 Units of Botox or Xeomin. Therefore, we dilute the 100 units vial
with 3.5 of NaCl, similar to the 4 mL dilution that was proposed from
Prof. Laskawi for sialorrhea treatments and modified by us.13 To gain
on the one hand safe and on the other, possibly longer lasting results,
we choose to add into the 100 vial of Botox or Xeomin 0.5 mL less
NaCl, as we intend to achieve a little higher toxicity per injection
point.
When we treat the gland via sonography assistance, the needle
tip is not always visualized. The depth of the treated tissue can be
estimated indirectly, through the visible intraglandular parenchymal
motion, whereas the substance is being applied. Diffusion phenomena
into periglandular muscles can be minimized, when botulinum is
placed within the submandibularis and as long as it is injected slowly
into the gland. Local anesthesia is never required, as we choose 30-33
Gauge and 12-15 inch long needles, which allow comfortable and well
tolerated injections. It is stated that informed written consent was
obtained for publication of the patients' images.
2 | DISCUSSION
Having treated 23 patients only in the last 18 months for benign,
bilateral submandibular gland hypertrophies, we have not experienced
any major complications under the above suggested method and cho-
sen dosage of botulinum toxin type A. Our patients were reviewed
after 2 weeks. Further touch-up injections could be administered
reaching a botulinum toxin dosage total up to 30 units, but due to a
satisfactory response our subjects did not underwent any additional
injection. Repeated injections are always necessary for long-term con-
trol, typically on the order of every 4 to 5 months. Thirteen patients
were treated just for an aesthetic improvement of their appearance,
9 patients because of sialadenosis with submandibular manifestation,
and 1 patient for recurrent, bilateral sialolithiasis of the submandibular
glands. Minor complications were appeared, where in 15 patients the
feeling of tension within the glands was for about 48 hours, which
was accompanied by some hypersensitivity in the treated area. Unilat-
eral bruising was reported in six patients. Eight patients complained of
sudden, short-lasting pain during injection, probably associated to a
contact of the needle with the lingual nerve. Adverse events like diffu-
sion of toxin in neighbored muscles, nerve palsy, tongue dysesthesia,
or xerostomia did not occur. Beyond the effectiveness of this proce-
dure, it is remarkable that botulinum toxin has a longer lasting dura-
tion on autonomic neurons as on muscles. It is observed that in
muscular tone treatments, the toxin acts positive for 3 to 4 months,
F IGURE 2 Demonstration of two
different submandibular gland injection
techniques with botulinum toxin type A:
Sonography-guided application on the left
and “blind” palpation technique on the
right picture
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whereas it lasts from 5 to 12 months in autonomic system indica-
tions.14 Laskawi et al published that the longest duration on an auto-
nomic nervous system dysfunction they treated conservative with
botulinum toxin type A was a patient with Frey's syndrome, where
the positive results lasted whole 27 months. The exact mechanism
behind this phenomenon is subject of further scientific research,
although some hypothetic approaches have been documented by
some authors.15 Our patients experienced an improvement in the size
of the treated glands from 2 to 10 days post injection, with an average
of 8 days. The suggested dosage and dilution of 3,5 mL for the
100 unit vial is turning to be effective. Although experienced injectors
might choose dosages up to 30 units of toxin per gland, we could
achieve satisfying results also with less injected units, while ensuring
safety for our patients. Even the sonographic two-dimensional mea-
surements (length and height) of the glands showed an improvement,
especially in the height, meaning a decrease in the volume of the
glands, which was estimated from 0.3 to 1.2 cm in some cases. This is
a significant result, as the average height of the treated glands
reached up to 2.4 cm. The comparison to other alternative and more
common approaches for controlling persistent glandular swellings
shows why the neurotoxin should replace techniques like oral anti-
cholinergic medication. Scopolamine and glycopyrrolate may work by
blocking the parasympathetic nervous system and innervation of the
salivary production, which leads indirectly to a shrinking of glandular
tissue, but they are associated with side-effects like behavioral
changes, severe constipation, etc.16 Invasive interventions like sub-
mandibulectomy might be another option to solve the hypertrophic
gland problem, but it is more aggressive as it entails the risk of a ramus
marginalis weakness of the mandibular nerve and therefore external
incisions are also necessary, which can have a negative impact on the
cosmetic outcome of the neck. Complications can be limited, when
choosing the proper neurotoxin injection technique and respect the
submandibular glands particular anatomic features. Although it is
important to note that the ideal dose has not yet been identified, we
recommend ultrasound controlled-botulinum toxin type A applications
as significant noninvasive methods that can act far from their thera-
peutic potential on controlling hypersalivation, also as elegant tools in
solving aesthetic disturbing conditions of benign submandibular
hypertrophies.
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